Partnering for Future Innovations

We have a long history of collaborative and supportive partnerships with top academic institutions and companies.

Nippon Shinyaku, Co., Ltd. (U.S. Subsidiary: NS Pharma, Inc.)

Capricor has entered into Exclusive Commercialization and Distribution Agreements with Nippon Shinyaku Co., Ltd., (US subsidiary: NS Pharma, Inc.) an experienced and well-resourced commercial partner for exclusive distribution of CAP-1002 for DMD in the United States and Japan. Nippon Shinyaku has been a trusted DMD partner for the community and has already established a respected infrastructure to support patients and their caregivers. If CAP-1002 is approved for DMD, we believe Nippon Shinyaku’s leadership in the space will serve CAP-1002 well in reaching more eligible patients who could potentially benefit from our therapy.

Other Supportive Collaborations

National Institutes of Health

  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Division of Microbiology and Infectious Diseases (DMID)

U.S. Department of Defense

United States Army Institute of Surgical Research (USAISR)

University of Rome

Cedars-Sinai Medical Center

Johns Hopkins University

California Institute for Regenerative Medicine (CIRM)

Partner with Us

We are actively exploring partnership opportunities to maximize the full potential of our platform and pipeline. To inquire about partnering opportunities: Contact Us